DEVELOP THE NEXT GENERATION OF PREDICTIVE DIAGNOSTICS
Cofactor’s multidimensional RNA biomarkers have the potential to change our ability to predict therapy response. Early results in recurrent and metastatic head and neck cancer show, quantitatively, that multidimensional biomarkers outperform today’s standard of care diagnostics. We’re partnering with disease experts to demonstrate utility in other indications through sponsored clinical studies.
Better tools are needed to provide clinicians and patients with a more accurate understanding of tumor response ahead of treatment decisions,” explained Douglas Adkins, M.D., who led the study. “The use of multidimensional biomarkers rather than single analyte biomarkers represents a promising new approach.
YOU MIGHT ALSO BE INTERESTED IN
Help us write the next chapter in human health and precision medicine.
Achieving true precision medicine requires a shift to multidimensional models.
Get the latest news on how we’re changing the biotech industry.
INDICATIONS WE’RE PURSUING IN IMMUNE-ONCOLOGY
Are you a medical oncologist, pathologist, or other clinical researcher with an active interest in one of the indications shown below? Contact us to learn about our sponsored research programs.
Contact us to participate in one of our sponsored retrospective or prospective studies, with full support provided by Cofactor Genomics.
OUR DIAGNOSTIC PIPELINE
A robust assay that has already been rigorously validated significantly lowers the barriers to adoption and makes sophisticated biomarkers, such as immune gene expression models, more broadly accessible.
– Andrew Aijian, Partner at DeciBio
Analytical Validation
Published in the Journal of Molecular Diagnostics, our peer-reviewed study demonstrates the performance of ImmunoPrism, our novel RNA-based immune profiling assay.
Our ImmunoPrism Assay
We’re making the future of diagnostics a reality. Cofactor has leveraged the power of machine-learning and RNA-seq to build gene expression models that capture complex biology and enable sensitive and specific quantification of immune cells in FFPE tissue samples. After generating a complete immune profile of each patient’s tumor, our Predictive Immune Modeling platform then combines signals to generate a multidimensional biomarker. Full statistical interpretation including ppv, npv, and ROC curves empower clinical interpretation – no biostats support required. We’ve developed the tools, now we need your expertise to bring these to the clinic.
